Thelansis’s "Psoriatic Arthritis (PsA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Psoriatic Arthritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Psoriatic arthritis (PsA) is a chronic, heterogeneous seronegative inflammatory spondyloarthropathy that develops in approximately 30% of patients with psoriasis. Driven by an aberrant immune response involving the TNF, IL-17, and IL-23 cytokine pathways, it causes progressive joint damage and profound physical disability. Clinically, PsA is characterized by a distinct constellation of features: peripheral synovitis, enthesitis, dactylitis, axial spondylitis, and characteristic nail dystrophy. Diagnosis is established clinically using the CASPAR criteria, integrating inflammatory articular disease with features like personal or family history of psoriasis, negative rheumatoid factor, and radiographic evidence of juxta-articular new bone formation. Therapeutic strategies in 2026 follow a strict treat-to-target approach aiming for minimal disease activity. Management utilizes NSAIDs for mild symptoms, conventional synthetic DMARDs like methotrexate, or highly effective advanced biologics targeting TNF-alpha, IL-17, and IL-23, alongside oral JAK inhibitors.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Psoriatic Arthritis (PsA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report
Our team will get in touch with you shortly about the Psoriatic Arthritis (PsA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report.